Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab

Multiple Sclerosis Journal

Volumn 19, Issue 9, 2013, Pages 1226-1229

  Blinkenberg, Morten ^a   Sellebjerg, Finn ^a   Leffers, Anne Mette ^a   Madsen, Camilla Gøbel ^a   Sørensen, Per Soelberg ^a  

^a Mental Health Services CPH   (Denmark)

Author keywords

IRIS; multiple sclerosis; natalizumab; PML

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; METHYLPREDNISOLONE; NATALIZUMAB; VIRUS DNA;

ADULT; ANTIBODY SCREENING; ARTICLE; BLOOD EXAMINATION; BREAST CARCINOMA; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; CEREBELLAR PEDUNCLE; CEREBELLUM CORTEX; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEMISPHERE; HERPES SIMPLEX; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LEG PARALYSIS; MOUTH INFECTION; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; MYCOSIS; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; POLYMERASE CHAIN REACTION; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REHABILITATION CARE; RELAPSE; REMISSION; TREATMENT DURATION; VERTIGO;

IRIS; MULTIPLE SCLEROSIS; NATALIZUMAB; PML;

ADENOCARCINOMA; ANTIBODIES, MONOCLONAL, HUMANIZED; BREAST NEOPLASMS; CEREBELLUM; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84880154812     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513481010     Document Type: Article

References (9)

1. Clifford DB, De Luca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol. 2010 ; 9: 438-446
2. Sørensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012 ; 18: 143-152
3. O'Connor PW, Goodman A, Kappos L, et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 ; 76: 1858-1865
4. Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011 ; 68: 186-191
5. Phan-Ba R, Lommers E, Tshibanda L, et al. MRI preclinical detection and asymptomatic course of a progressive multifocal leucoencephalopathy (PML) under natalizumab therapy. J Neurol Neurosurg Psychiatry. 2012 ; 83: 224-226
6. Vennegoor A, Wattjes MP, van Munster ET, et al. Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. Neurology. 2011 ; 76: 574-576
7. White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy - revisited. J Infect Dis. 2011 ; 203: 578-586
8. Metz I, Radue EW, Oterino A, et al. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy. Acta Neuropathol. 2012 ; 123: 235-245
9. Antoniol C, Jilek S, Schluep M, et al. Impairment of JCV- specific T-cell response by corticotherapy: Effect on PML-IRIS management?. Neurology. 2012 ; 79: 2258-2264